Command Palette
Search for a command to run...
Valiant Laboratories
NSE: VALIANTLABBSE: 543998PHARMACEUTICALS & BIOTECHNOLOGYPHARMACEUTICALS
Market Cap
--
P/E Ratio
0.00
P/B Ratio
0.00
ROE
0.00%
ROA
0.00%
Debt/Equity
0.00
Book Value
₹0.0
EPS
₹0.0
About Valiant Laboratories
Valiant Laboratories engaged in manufacturing and dealing in Pharmaceuticals and speciality chemicals.
Valiant Laboratories Limited was originally formed as a Partnership Firm as `M/s. Bharat Chemicals' through deed of partnership dated October 17, 1980. The said Partnership Firm, M/s. Bharat Chemicals thereafter converted into a Public Company to "Valiant Laboratories Limited" via Certificate of incorporation dated August 16, 2021 issued by the Central Registration Centre, Registrar of Companies. The Company is an Active Pharmaceutical Ingredient (API) / Bulk Drug manufacturing company having focus on manufacturing of Paracetamol. The Company gradually, commenced manufacturing of Paracetamol by late 1982. Paracetamol (Scientific name: Acetaminophen or para-hydroxyacetanilide - C8H9NO2), is one of the most commonly taken analgesic worldwide and is recommended as the first-line therapy in pain conditions by the World Health Organization (WHO). Paracetamol has several applications such as usage in treatment of headaches, muscle aches, arthritis, back aches, toothaches, cold and fever. It manufacture Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of customers. Paracetamol is available in a variety of forms including syrup form, regular tablets, effervescent tablets, injection, suppository, and other forms. Paracetamol is often found combined with other drugs in many over the counter (OTC) allergy medications, cold medications, sleep medications, pain relievers, and other products. Presently, the Company is engaged in manufacturing and dealing in Pharmaceuticals and specility chemicals. The manufacturing facility is located at Tarapur Industrial Area, Boisar in the State of Maharashtra, with an annual installed capacity of 9,000 MTPA. Within the Manufacturing Facility located at Tarapur Industrial Area, Palghar, Maharashtra, the Company has an in-house R&D infrastructure which is equipped with analytical laboratory and infrastructure for developmental activities in existing product. The Company is promoted by Shantilal Shivji Vora, Director and Dhanvallabh Ventures LLP (DVL). In July, 2022 the Company formed its wholly owned subsidiary, Valiant Advanced Sciences Private Limited (VASPL) to diversify the business activities. The Company launched a public issue comprising a fresh issue of 10,890,000 equity shares of Rs 10 each by raising funds of Rs 15.24 crore on October 03, 2023. Company enhanced the manufacturing capacity of the Tarapur plant from 750 MT to 900 MT per month in FY25.
Price Action • VALIANTLAB
Financial Statements
Consolidated & Standalone Reports
| Metric | TTM | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 |
|---|---|---|---|---|---|---|
Total Revenue | 192.83 | 138.79 | 191.73 | 338.77 | 293.47 | 183.78 |
Operating Expenses | 183.12 | 138.04 | 190.46 | 298.82 | 249.2 | 132.37 |
Operating Profit | 6.87 | -4.68 | -8.41 | 35.09 | 42.32 | 50 |
Operating Margin (%) | - | -3.37 | -4.39 | 10.36 | 14.42 | 27.21 |
Total Expenses | - | 140.24 | 192.49 | 300.64 | 251.77 | 136.76 |
EBITDA | - | 0.75 | 1.27 | 39.95 | 44.27 | 51.41 |
EBITDA Margin (%) | - | 0.54 | 0.66 | 11.79 | 15.08 | 27.98 |
Interest Expenses | 0.33 | 0.18 | 0.08 | 0.25 | 0.07 | 1.78 |
Depreciation | 2.04 | 2.02 | 1.95 | 1.56 | 2.49 | 2.61 |
Profit Before Tax (PBT) | 7.35 | -1.45 | -0.75 | 38.14 | 41.7 | 47.02 |
Tax Expenses | 0.53 | 0.7 | -1.09 | 9.14 | 14.21 | 16.43 |
PAT Before Extraordinary Items | - | -2.15 | 0.34 | 29 | 27.5 | 30.59 |
Net Profit | 6.82 | -2.15 | 0.34 | 29 | 27.5 | 30.59 |
Net Profit Margin (%) | - | -1.61 | 0.18 | 8.68 | 9.43 | 16.77 |
EPS (Adjusted) | - | -0.4 | 0.06 | 5.34 | 5.06 | 5.63 |
Valuation & Key Ratios
Performance Metrics
| Metric | TTM | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 |
|---|---|---|---|---|---|---|
Book Value Per Share | - | 53.94 | 54.52 | 30.86 | 43.89 | 84.36 |
Return on Assets (ROA) % | - | -0.67 | 0.1 | 13.62 | 15.12 | 28.77 |
Return on Equity (ROE) % | - | -0.91 | 0.14 | 28.85 | 38.47 | 34.53 |
Return on Capital Employed (ROCE) % | - | -0.42 | -0.22 | 23.66 | 31.55 | 53.97 |
Profitability Ratios | - | - | - | - | - | - |
Liquidity Ratios | - | - | - | - | - | - |
Valuation Ratios | - | - | - | - | - | - |
Debt to Equity Ratio | - | 0.25 | 0.25 | 0.59 | 0.85 | 0 |
Featured Insight
No recent news available
Key People
M
Mr. Paresh S. Shah
Executive Director,Whole Time Director,Chief Financial Officer,Co-Founder & Promoter
A
Akshay Gangurde
Company Secretary,Compliance Officer
M
Mr. Bhupendra Raul
Manager(Qa)
M
Mr. Shivaji Katkar
Plant Manager
M
Ms. Kiran Mudaliar
Assistant Manager(Accounts)
M
Mr. Nilesh Patil
Head(Analytical.)
M
Mr. Bhanudas Patil
Manager(Qc)
M
Ms. Meghana Wasnik
Head(R & D)